Save billions or stick with Humira? Drug brokers steer Americans to the costly choice

Humira has enjoyed high-priced U.S. exclusivity for 20 years. Its challengers could save the health care system $9 billion and herald savings from the whole class of drugs called biosimilars.

Related Keywords

Poland ,United Kingdom ,New York ,United States ,Brooklyn ,Kentucky ,Denmark ,Tennessee ,California ,American ,Americans ,Cora Opsahl ,Madelaine Feldman ,Kaiser Permanente ,Greg Baker ,Alex Jung ,Kevin Ali ,Keith Athow ,Coherus Biosciences ,Antonio Ciaccia ,Rachel Shubert ,Richard Gonzalez ,Siddharth Singh ,Juliana Reed ,Paul Holmes ,Mark Cuban ,Michael Thompson ,Mary Beth Lang ,Midwest Business Group On Health ,Bj Health Fund ,Health News ,Kroger ,National Alliance Of Healthcare Purchaser Coalitions ,American Gastroenterological Association ,American College Of Rheumatology ,Biosimilars Forum ,Service Employees International Union ,Arthur Allen ,Williams Barber Morel ,Express Scripts ,Federal Trade Commission ,Blue Shield ,Cost Plus Drugs ,Sue Lee ,National Alliance ,Healthcare Purchaser ,Midwest Business Group ,Marcus Snow ,American College ,New Orleans ,Gastroenterological Association ,Inflation Reduction Act ,Rich Lieblich ,